SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the appointment of John L. LaMattina, Ph.D. to the Company’s Board of Directors. Dr. LaMattina previously served as a senior R&D executive at Pfizer Inc. He is currently a senior partner at PureTech, a venture capital firm focusing on biotech investments, and serves on numerous Boards including Human Genome Sciences. Dr. LaMattina’s appointment increases the number of Ligand directors to eight.
